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Abstract
Polycystic ovarian syndrome (PCOS) is a reproductive and endocrine disorder in women of
childbearing age. This disorder includes multiple clinical manifestations, namely insulin
resistance (IR) and infertility related to hormonal imbalances and anovulation. Despite being a
common condition, its etiology and treatment modalities remain poorly defined. Without
proper understanding and management of the condition, women may suffer numerous
complications besides infertility such as diabetes mellitus type II (DMII), endometrial cancer,
and cardiovascular disease. Therefore, further research is critical. This integrative
review will create a comprehensive understanding of PCOS' pathophysiology, potential
complications, treatment methods, and nursing considerations to promote the health and
well-being of women affected by this condition.
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Polycystic Ovarian Syndrome and Insulin Resistance:
An Evaluation of Treatment Modalities and Complication Prevention
Polycystic ovarian syndrome (PCOS) is an endocrine and reproductive disorder that
affects approximately one in ten women. Especially when combined with insulin resistance (IR),
PCOS causes systemic manifestations for women that negatively impacts their daily lives.
However, due to the multifaceted nature of its etiology and clinical presentation, treatment
modalities are primarily centered around symptom management. However, this does not resolve
the underlying hormonal imbalances that cause ovarian dysfunction and other sequelae.
Additionally, some physicians may be quick to prescribe combined oral contraceptives (COCs)
for PCOS management without taking other possible treatments into consideration (Altinok et
al., 2018; Morgante et al., 2018). These factors may be combined with a lack of patient
knowledge or improper prevention, which can result in poor management of potential long-term
multiorgan complications (Palomba et al., 2015; Berni et al., 2018). As such, many patients
receive inadequate care of their chronic health condition that drastically interferes with their
well-being. Considering the high prevalence of PCOS-IR and the severity of its complications,
conducting research and providing thorough patient education regarding the best treatment
modalities and complication prevention methods should be a high priority in nursing practice.
Pathophysiology
Etiology
There are numerous hypotheses regarding the etiology of PCOS; however, it remains
largely undefined at present due to its multifactorial nature. The key factors identified in PCOS
etiology are exposure to excessive androgens in utero and throughout life, obesity, genetics, and

5
hyperinsulinemia with IR. Even so, this varies among patients, leaving individuals with unique
etiologies and medical needs.
High levels of androgens in utero cause changes within the hypothalamus-pituitaryovarian axis that manifest as the endocrine irregularities of PCOS during puberty (De Leo et al.,
2016). This is especially true if other factors compound with genetic and environmental factors
in utero and throughout life. Typically, the fetus would be protected from excessive androgens
by aromatase produced by the placenta. However, inhibited aromatase production may occur in a
small number of women. Additionally, pregnant women with preeclampsia or PCOS may have
impaired estrogen synthesis, which would impair regulation of fetal testosterone. Maternal
hyperandrogenism may also increase the risk of PCOS in a female fetus due to the combination
of cross-generational genetics and environmental factors. As such, epigenetics may be involved
in reprogramming fetal reproductive tissue to contain abnormalities (De Leo et al., 2016).
The evidence regarding the effect of elevated testosterone is paired with previous
research done by Abbott et al. (2005) demonstrating PCOS in rhesus monkeys and sheep when
exposed to injections of testosterone prenatally. In these animal studies, pathologic changes in
ovarian function, fertility, luteinizing hormone (LH) secretion, and IR were evident. Not only
was ovarian dysfunction evident, animals in the study exhibited masculinization, irregular
behavior, and other pathophysiologic changes. The conclusions of the study relating elevated
testosterone in mammals are comparative to human pathophysiology due to the similarities in
fetal programming of the female reproductive system, especially regarding ovarian development
and oogenesis (Abbot et al., 2005).
Additionally, Fillipou and Homburg (2017) discuss since some women have polycystic
ovaries prior to puberty, the origin of their condition is likely affected by conditions in utero and
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compounded by genetic vulnerability. In such instances, the ovaries are reprogrammed with
abnormal functionality. This is further confirmed through evaluations of placentas from PCOS
women, which demonstrate a hyperandrogenic environment that alters placental tissue. The
placentas were found to have decreased P450 aromatase and other altered enzymes related to
steroid synthesis. Maternal hyperandrogenemia may also impact the fetal development of
ovaries, which occurs throughout gestation. Both gonadotrophins and paracrine hormones, such
as insulin-like growth factor (IGF), interact with steroidogenic enzymes and signaling pathways
to develop the ovaries. Once this process is completed in mid-gestation, the fetal ovaries can
produce androgens in utero, such as in response to insulin levels. Consequently, a combination of
environmental androgen exposure with genetic variability is indicated (Filippou & Homburg,
2017).
Filippou and Homburg (2017) elaborate upon the effects of prenatal exposure to
androgens and alterations in related genes using research that demonstrated elevated antiMullerian hormone (AMH) levels in connection with PCOS. Elevated AMH production by
granulosa cells within the ovaries strongly inhibits follicular growth instead of providing proper
physiologic maintenance of the ovulation cycle. The higher the AMH concentration, the more
severe the degree of anovulation and amenorrhea in women with PCOS. Although there is a
correlation between hyperandrogenism and elevated AMH, this does not indicate direct
causation. At present, the cause of elevated AMH is unknown, but in some individuals, it may be
caused by hypomethylation of the AMH gene, which would lead to intrinsic over-expression and
increased synthesis of AMH (Fillipou & Homburg, 2017). Similarly, a study conducted by
Gorsic et al. (2019) identified multiple genetic variations along the AMH pathway that are linked
to PCOS through targeted resequencing of coding and regulatory components of the affected
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genes. These variants along AMH and AMHR2, a specific AMH receptor, impair proper AMH
regulation and subsequently inhibit ovulation cycles (Gorsic et al., 2019).
As indicated by De Leo et al. (2016), genetics play a strong role in the development of
PCOS for many women. While the precise mechanism for genetic inheritance has not been
determined thus far, both autosomal dominant transmission and polygenic transmission
mechanisms have been postulated. The particular genes being researched are those involving the
synthesis and regulation of androgens and insulin. Additionally, individuals with proinflammatory genotypes or irregular folliculogenesis may be linked to PCOS based on recent
studies. Each of these previous hypotheses require extensive further research. Currently, only
two susceptibility genes have shown to be identified: allelic variants of fibrillin-3 (FBN3) and
variants of luteinizing hormone receptors (LHR). The A8 variant of FBN3 has shown to cause
insulin resistance while altered LHR may cause dysregulation of ovulation, androgen production,
and adipogenesis. For fetuses with any of the mentioned genetic abnormalities, ovarian
dysfunction in utero may be present, causing excessive androgens due to irregular responses to
maternal human chorionic gonadotropin (hCG), demonstrating further links to hyperandrogenism
in utero as described previously (De Leo et al., 2016).
Beyond the potential genetic mutations directly controlling LH and androgen secretion,
genetic mutations in the hypothalamic-pituitary-ovarian (HPO) pathway beginning with altered
gonadotropin releasing hormone (GnRH) must be considered. Shaaban et al. (2018) concluded
genetic and metabolic pathophysiological mechanisms for PCOS regarding GnRH contribute to
its etiology. These alterations would indicate dysfunctional hypothalamic regulation of GnRH
secretion along with faults in the GnRH receptor (GnRHR) gene, leading to improper levels of
androgens, LH, and follicle stimulating hormone (FSH). PCOS women typically have high LH
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concentrations due to GnRH excess. This consequently prevents proper fluctuations in LH levels
that would normally produce follicle development and ovulation. Likewise, altered GnRH may
also stimulate excess androgens, which prevents proper ovulation and negatively impacts female
reproductive health, as established throughout this paper and indicated by Figure 1 (Shaaban et
al., 2018).
De Leo et al. (2016) and Filippou & Homburg (2017) further identify metabolic factors
as pertinent to the development of PCOS. IR is not only a common clinical manifestation
associated with PCOS, it is also related in its pathogenesis. It has been established
hyperandrogenism is linked to increased IR and insulin activity in utero, which also inhibits
aromatase levels. Beyond IR and hyperinsulinemia consequent to hyperandrogenism, these
factors are potential synergistic agents in PCOS etiology. This is due to their relationship with
ovarian development and function throughout life. Along with hyperandrogenism,
hyperinsulinemia is a contributor to elevated AMH, which negatively impacts ovulation as
described earlier. Similarly, any other metabolic conditions, especially those experienced
prenatally like impaired intrauterine nutrition and preeclampsia, are potential, though less
influential, contributors to PCOS development due to their connection with IR and altered
steroidogenesis (De Leo et al., 2016; Filippou & Homburg, 2017).
Condorelli et al. (2017) describe that PCOS-IR individuals have an abnormal biologic
response to insulin where “anomalies involving the secretion of pancreatic cells (abnormal
insulin or incomplete conversion of proinsulin to insulin), high blood concentration of hormones
counterregulatory to insulin, anti-insulin antibodies or antibodies anti-insulin receptor, and also
target organs disorders (because of a reduced quantity of insulin receptors or post-receptor
defects)” (pp. 665) are present. As such, there is a significant reduction in peripheral insulin
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sensitivity that interferes with the body’s ability to regulate blood glucose levels, uptake glucose
for cell metabolism, and increases glucose storage within adipose tissue. Consequently, the body
produces excess insulin to counteract IR, which further perpetuates the problems of glucose
irregularities, causes pancreatic beta cell dysfunction long-term, and may lead to liver
dysfunction in the form of nonalcoholic fatty liver disease (NAFLD) or nonalcoholic
steatohepatitis (NASH) in some women. Decreased secretory-cell activity is further noted when
evaluating the first phase insulin response (FPIR) that occurs when glucose initially enters the
bloodstream. This impaired secretory-cell function in response to glucose demonstrates the
multifaceted dysfunction of insulin regulation within the PCOS-IR population (Condorelli et al.,
2017).
Mcewen and Hartmann (2018) also elaborate upon the connection between PCOS and IR
by discussing the apparent dysfunction of PCOS individuals to properly respond to insulin in
both the ovaries and metabolically. In PCOS, impaired insulin-mediated glucose utilization
within tissues along with paradoxical ovarian insulin sensitivity has been noted. This creates a
hyperglycemic state along with increased androgen production by theca cells in the ovaries and
within adipose tissue (Mcewen & Hartmann, 2018).
Clinical Manifestations
The type and severity of clinical manifestations of PCOS vary widely among women.
Similarly, symptoms may change throughout a patient’s life depending on management of their
condition and other health factors. The most common and substantive clinical manifestations
discussed within this review will include: oligomenorrhea and oligoovulation; polycystic ovaries;
hyperandrogenism; weight gain and obesity; and mood liability and headaches (Palomba et al.,
2015). There are many additional symptoms and sequelae associated with PCOS. However, for
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the purpose of this integrative review, the focus will be to discuss those symptoms most
commonly seen with PCOS.
Oligomenorrhea, Oligoovulation, and Polycystic Ovaries
Due to the imbalance of multiple reproductive hormones, eggs with the ovaries do not
mature appropriately (Patel, 2018). When hormones are improperly regulated, instead of being
released into the fallopian tube during ovulation, eggs remain in the antral follicles and become
cysts. These cysts are filled with water and may become as large as 10cm within the ovaries.
When ovulation cannot occur, this typically prevents menstruation. However, in some cases,
menstrual bleeding may occur despite an anovulatory cycle and may be paired with the absence
of cramps or premenstrual syndrome (PMS). More mild hormonal imbalances result in
oligomenorrhea with varying lengths in between cycles, whereas others present with complete
amenorrhea and anovulation. In both instances, medications to prevent endometrial hyperplasia
and other complications may be indicated. Follicular development is partially impaired by
hyperresponsive ovarian theca cells that are stimulated by excess insulin to produce excess
androgens. This is compounded by disrupted GnRH secretion that leads to irregular LH and FSH
release, among other hormones, and consequent menstrual irregularities. When any one or
multiple hormones are disrupted, it can create a compounding effect as other hormones become
disrupted as well, leading to complex endocrine dysfunction (Patel, 2018).
Hyperandrogenism
Pfieffer (2019) details that elevated androgen levels in women disrupts more than just the
menstrual cycle. Hyperandrogenism may stem from multiple factors, such as polycystic ovaries,
obesity, and poorly regulated hormone pathways. Acne and hirsutism are two clinical
manifestations among multiple visible symptoms of hyperandrogenism that pose difficult to
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manage for women with PCOS. Increased acne occurs consequentially to seborrhea, which
makes the skin prone to bacterial growth within clogged pores. For many women, acne is severe
in nature and may be classified as cystic lesions that are resistant to common acne treatments.
Hirsutism is defined as the appearance of excess body hair in women on the face, chest, back, or
extremities. Obesity intensifies the severity in many women. The severity may be evaluated
based on the Ferriman-Gallwey Scale, but it used only for subjective purposes. Interestingly,
male pattern baldness has also been correlated to hyperandrogenism and occurs in approximately
ten percent of PCOS women. Often, hormonal acne and hirsutism are difficult to reduce without
the use of antiandrogen medications such as spironolactone. While acne and hirsutism typically
do not interfere with general health and well-being, it may cause lowered self-esteem related to
perceptions of beauty and social implications (Pfieffer, 2019).
Weight Gain and Obesity
In a study conducted by Broskey et al. (2018), it was established that many women with
PCOS-IR demonstrate metabolic inflexibility due to the body’s inability to regulate insulin
production and use during both fed and fasting states. In a healthy individual, metabolic
flexibility is described as the capacity to oxidize lipids in a fasted state and then switch to using
carbohydrates in a fed state. The improper stimulation and use of insulin leads to prolonged
hyperglycemic states and increases stress on the pancreas’ beta cells. This is similar to metabolic
changes present in patients with DMII and also increases the likelihood of DMII development in
PCOS patients. Additionally, the metabolic inflexibility increases the risk of weight gain and
obesity due to inhibited non-oxidative glucose metabolism. Not only is glucose retained in the
body as fat, the ability of patients to lose weight, even with appropriate diet and exercise, is
inhibited because of their inhibited metabolic processes. The study also reiterated the propensity
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of PCOS women to have high levels of free testosterone and elevated free androgen index. As
such, the combination of PCOS with IR statistically increases the chances of weight gain and
obesity (Broskey et al., 2015).
Mood Liability and Headaches
Palomba et al. (2015) along with the NICHD Staff (2017a) discuss that women with
PCOS may have mood liability due to hormone fluctuations. Though this can be commonly
associated with premenstrual syndrome (PMS) in the general female population, the severity and
variance in presentation in PCOS patients is substantial. Many PCOS patients report mood
liability that is not strictly associated with their menstrual cycle. This may progress to anxiety
and depression when combined with other factors, as discussed later. In any case, the feelings of
sadness, irritability, anger, or other unpleasant emotions associated with mood liability have the
potential to drastically interfere with a woman’s well-being. For some women, hormone
fluctuations also increase the risk of chronic headaches or migraines. This may be worsened by
PMS or by medications such as birth control that further impact mental health. IR may also play
a significant role in both mood-related disorders and headache frequency related to metabolic
abnormalities that affect regulatory pathways within the brain and endocrine system (Palomba et
al., 2015; NICHD Staff, 2017).
Complications
Infertility, Miscarriage, and Pregnancy Complications
Consequential to hormonal dysregulation and oligoovulation, women often have
difficulty conceiving. PCOS patients experience reduced frequency of mature egg release from
the ovaries along with hormonal conditions not conducive to pregnancy maintenance. This
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results in a higher rate of infertility and miscarriage among the PCOS population (Palomba et al.,
2015).
Palomba et al. (2015) describes metabolic abnormalities that predispose women to
pregnancy complications are also present in PCOS women. This is namely seen in the
significantly increased risk of gestational diabetes mellitus (GDM), which may be upwards of
threefold. IR along with the commonality of obesity put women at increased risk. IR may be
worsened during pregnancy due to increased stress on the body and elevated metabolic demand.
When the body cannot compensate adequately, GDM develops. This poses risks for both mother
and baby such as premature birth, maternal and fetal development of DMII later in life, and
cesarean delivery (Palomba et al., 2015).
According to Palomba et al. (2015), pregnancy-induced hypertension and preeclampsia
are significant risk factors for PCOS patients due to a variety of factors. PCOS patients may be at
a threefold greater risk than the average woman for developing these conditions. This increases
the risk of prolonged hospitalization, bed rest, premature delivery, and potentially serious
maternal and fetal health outcomes (Palomba et al., 2015).
Diabetes Mellitus Type II
Palomba et al. (2015) reiterates women with PCOS are statistically more likely to
develop DMII. This is consequent to IR, along with other factors such as obesity and poor
lifestyle habits. As a woman with IR ages, her ability to regulate blood glucose and transport it
into cells decreases. This occurs as the beta cells of the pancreas become overworked and
produce insufficient or dysfunctional insulin. Additionally, insulin receptors throughout the body
may not respond to insulin properly. These factors potentiate the consequences of IR and may
progress to DMII. Once DMII is diagnosed, PCOS patients may have difficulty managing it due
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to hormone fluctuations, elevated androgens that reinforce IR, and challenges losing weight
(Palomba et al., 2015). DMII poses significant health risks on its own, which are heightened
when combined with PCOS-IR and described throughout this integrative review.
Condorelli et al. (2017) elaborates on the intricate pathophysiological nature of PCOS
and IR that is related to genetic and hormonal mechanisms in conjunction with dietary and
exercise considerations. There are a variety factors that affect PCOS and the development of
DMII, which should be considered as part of PCOS patients’ health maintenance. Patel (2018)
also investigates the multifactorial, interdependent aspects that are both causative factors and
subsequent consequences of DMII. PCOS-IR’s complex presentation of hormonal and metabolic
irregularities, weight gain, cardiovascular disease, and other characteristics both prior to and
after DMII development cause researchers to continue to investigate disease manifestation,
prevention methods, and treatment options (Patel, 2018).
Cardiovascular Disease
Palomba et al. (2015) elaborates that PCOS-IR women have an impaired ability to
process glucose, leading to persistent hyperglycemic states. This is especially true if women do
not regulate their diets, have prediabetes or unregulated DMII, and/or struggle with obesity. Each
of these factors, particularly when combined with the potential for altered lipid metabolism,
raises a woman’s risk of cardiovascular disease. The numerous sequelae of these comorbidities,
such as hypertension and hypercholesterolemia, increase the likelihood of plaque development
within blood vessels. As lipids accumulate, the risk of myocardial infarction is significant.
Additionally, hyperglycemic states increase the likelihood of thrombi as glucose irritates and
damages the cardiovascular endothelium. Once the vasculature is damaged, inflammation
worsens the condition by propagating clotting and further raising cortisol levels, which only
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propitiates the hyperglycemia. As such, those with DMII are at highest risk for developing
cardiovascular disease and experiencing complications due to the compounding nature of PCOS
and DMII on the body. Further research is necessary regarding the complex relationship between
PCOS and cardiovascular disease both with and without the presence of factors such as IR and
obesity (Palomba et al., 2015).
For PCOS women on hormonal birth control, the risk of cardiovascular disease is further
elevated. Discussed in further detail later, these medications have known risk factors associated
with elevated clotting risks and hypertension (Sanoski & Vallerand, 2019). Women over 35
years old or with cardiovascular conditions are warned against taking these medications for this
very reason. As such, there is a conflict between prescribing birth control for menstruation
regulation and protecting PCOS patients’ cardiovascular health (Sanoski & Vallerand, 2019).
Non-Alcoholic Fatty Liver Disease
Petta et al. (2017) explains that when IR and hyperandrogenism are present, PCOS
patients have a higher risk of developing non-alcoholic fatty liver disease (NAFLD). This stems
from altered lipid metabolism that increases the likelihood of adipose tissue depositing within
tissues, primarily the liver. Another consideration that increases risk is the presence of obesity
due to the higher percentage of adipose tissue within the body and obesity’s impact on
metabolism and IR as described earlier. The study by Petta et al. (2015) observed that steatosis
was present in 68.8% of the studied patient population. This and other statistical analysis
concluded that PCOS can be classified as an independent risk factor for development of
steatosis. Additionally, liver steatosis may cause impaired liver function. This may remain
asymptomatic depending on severity, but can become problematic as it begins to impair liver
function. As steatosis progresses, women may develop elevated levels of aspartate
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aminotransferase (AST) and alanine aminotransferase (ALT). AST and ALT are two key liver
enzymes involves in glycogen production. When elevated, they indicate tissue damage within the
liver. In severe cases, this could further progress to nonalcoholic steatohepatitis (NASH). As
such, evaluating PCOS patients for the presence of NAFLD and altered liver function is critical
to diagnosis and management of potential liver damage (Petta et al., 2017).
Depression and Anxiety
Palomba et al. (2015) along with Berni et al. (2018) explain that women with PCOS are
prone to depression, anxiety, and other mood-related disorders due to hormone fluctuations along
with psychological stress regarding PCOS complications, poor body image, and other factors.
Depression and anxiety are often disregarded as symptoms of PCOS; however, evidence displays
that endocrine and metabolic abnormalities have psychological ramifications among the PCOS
population. Similarly, poorly managed mental health has potentially severe consequences, such
as inhibited health maintenance and suicidal ideation. Mood liability is often described as a key
symptom among PCOS patients (Palomba, et al., 2015; Berni et al. 2018).
A woman’s difficulty with body image and low self-esteem associated with PCOS often
stems from hirsutism and obesity. These may make a woman feel unfeminine, especially if she is
criticized by others. This is compounded by infertility, which is disrupts what many individuals
would consider an integral aspect of womanhood. Women may experience both anticipatory
grief over potential infertility and disenfranchised grief over current infertility and miscarriages.
Infertility may also lead to anxiety over societal perceptions and stress within romantic
relationships related to intimacy, family ideals, and health maintenance. Additionally, women
may lack social support, struggle with isolation, or feel overwhelmed by the consequences of
having a health condition largely out of their control. Any one or multiple of these contributes to
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PCOS patients’ risk of depression and anxiety, indicating the need for increased screening of
mental health disorders by physicians (Berni et al., 2018).
The severity of PCOS-related mental and emotional symptoms may be worsened by
hormonal birth control in some women. These medications can increase mood liability and may
worsen depression due to estrogen and progesterone’s interaction with brain chemistry (Sanoski
& Vallerand, 2019). This is especially true for women who experienced symptoms of anxiety
and depression prior to taking birth control or for women prescribed higher dose estrogen COCs.
In such instances, the risk of severe depression and suicidal ideation is a clear contraindication of
hormonal birth control. As such, other treatment options must be considered. However, due to
limited gynecological knowledge and treatment options, women are often left with poorly
managed PCOS and its related conditions.
Endometrial Hyperplasia and Uterine Cancer
Patel (2018) states that “PCOS can put a female at the risk for uterine cancer, as the
prevailing high estradiol level and the lack of progesterone due to ovarian malfunction increases
the risk of endometrial hyperplasia” (p. 28). When a woman does not have a regularly occurring
menses, the endometrial lining built up during the menstrual cycle thickens and may develop into
endometrial hyperplasia. This overgrowth of tissue within the uterus further interferes with
fertility and increases a woman’s risk for abnormal cell development, including the proliferation
of cancerous tumors. The more severe the hyperplasia and the longer the excess endometrial
tissue sits within the uterus, the more likely cellular mutations will occur. These risks remain
relatively low for women who menstruate at least every 3 months. However, PCOS with severe
oligomenorrhea or amenorrhea must be evaluated and treated for these potential complications
(Patel, 2018; Palomba et al., 2016).
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To combat the risk of hyperplasia in oligoovulation, women are typically prescribed
hormonal birth control, such as COCs or progesterone only pills (POPs), to force the regular
occurrence of menstruation (Kriedt et al., 2019; De Leo et al., 2016). Typical guidelines state
menstruation should occur at least every 2-3 months to prevent overgrowth (De Leo et al., 2016).
Current research has inconclusive or conflicting data as to whether metformin is effective in
reducing endometrial hyperplasia risk (Palomba et al., 2015). Although hormonal birth control
options may accomplish the goal of preventing hyperplasia, they have numerous side effects and
often neglect to address the underlying health and reproductive concerns of PCOS, as discussed
later.
Treatment Modalities and Nursing Considerations
Lifestyle Modification
The first line of treatment for PCOS, much like many diseases, is lifestyle modification.
Avoiding unnecessary medications or medical procedures facilitates sustainable health, reduces
health costs, and minimizes the risks of side effects (Schlesinger & Grob, 2017). The many
systemic complications of PCOS reiterates the necessity of holistic care. PCOS patients should
speak with their physicians regarding beneficial changes in diet, exercise, and other aspects of
daily living that affect both mental and physical wellbeing. Nurses are especially important in
promoting lifestyle modification as they build rapport and have considerable patient interaction
with their patients. An overview of long-term complication management, including clinical
assessment and therapeutic approaches, by Palomba et al. (2015) is included in Figure 3.
Dietary Modification
The importance of a healthy diet in disease prevention and management must be
reiterated for patient well-being and is one of the key treatment considerations. This is especially

19
true for PCOS patients. Not only does incorporating a healthy balance of carbohydrates, proteins,
and fats encourage proper weight management and prevention of countless diseases, it may
reduce the risk PCOS sequelae, such as DMII (Merkin et al., 2016). Before simply prescribing
medications, PCOS patients should initiate a healthy diet and evaluate its effectiveness in
reducing symptoms. However, this requires considerable patient education on behalf of the
healthcare provider on what is considered a healthy diet and why is has the potential to impact
the courses of their chronic condition.
Current research is investigating the potential benefits of gluten free and dairy free diets.
Though not widely discussed in practice currently, many patients may see improvements when
instituting one or both dietary changes due to their potential to exacerbate insulin resistance and
hormone disruption (Merkin et al., 2016). In any case, adhering to guidelines set forth within the
Dietary Guidelines for Americans, as set forth by the United States Department of Agriculture
and Department of Health and Human Services, can improve general health. Overall, research by
Merkin et al. (2016) demonstrates the importance of dietary regimen adherence and weight
management as keys to PCOS management.
General Dietary Recommendations. According to Dutkowska et al. (2019), eating
carbohydrates with a low-glycemic index has shown to improve insulin sensitivity and reduce
markers of inflammation. Whether for weight loss or weight maintenance, restricting the amount
of lower quality carbohydrates is beneficial for menstrual cycle regulation and symptom
reduction. Additionally, increasing the amount of protein to 20%-35% of daily dietary intake
may help increase weight loss, promote normal metabolic parameters, and reduce depression.
Increasing the number of omega-3 fatty acids may also promote regular menstruation in addition
to their ability to improve insulin sensitivity. Consuming saturated fats and advanced glycations
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end products (AGE) should be minimized dur to their role in stimulating proinflammatory
proteins and interfering with metabolism. In general, many of these recommendations apply to
multiple diseases, however, PCOS patients should become aware of how these specific dietary
changes may have significant impacts on their long-term wellbeing (Dutkowska et al., 2019).
Gluten Free. Merkin et al. (2016) explains that gluten, simple carbohydrates, and added
sugars are difficult for women with PCOS-IR to process due to their inability to regulate insulin
and blood glucose levels. This leads to spikes in blood sugar, increased insulin production, and
higher storage of carbohydrates as adipose tissue. In turn, weight gain becomes problematic
along with exacerbated hormone irregularities. As previously explained, hyperinsulinemia
stimulates excess androgens and worsens PCOS symptomatology. Research has indicated gluten
sensitivities may be present in some PCOS patients, as gluten-free diets have shown to reduce
symptoms in combination with the reasons listed previously. There is question as to the exact
mechanism of hormone disruption associated with gluten. Current suggestions include the
phytoestrogen production of gluten along with the influence of agricultural pesticides on the
endocrine system (Merkin et al., 2016).
Dairy Free. As stated by Merkin et al. (2016), dairy has the potential to increase
inflammation and raise testosterone levels, which can worsen symptoms in women with PCOS.
The whey component of dairy is especially insulinotropic and may exacerbate hyperinsulinemia
and hyperandrogenism seen in PCOS patients, especially those with IR. This suggests that PCOS
patients should avoid foods and nutritional supplements that have whey as an ingredient and
reduce overall dairy consumption. For some, eliminating dairy from their diets may be one
beneficial component in managing PCOS (Merkin et al., 2016). However, more research is
necessary to evaluate its effectiveness in comparison to other treatment modalities. There is not
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enough current research to definitively conclude whether or dairy is a significant contributor to
PCOS presentation. Becoming dairy free should be done with discretion and under supervision
of a physician.
Regular Exercise
Regular aerobic exercise has proven to improve health in a variety of ways for all
individuals. Specifically in PCOS patients, aerobic exercise has the ability to promote a healthy
metabolism and insulin usage, increase weight loss or promote weight management. However
intense aerobic exercise regimens may stress the endocrine system and cause elevated cortisol
release, which promotes inflammation and hormone imbalances in PCOS (Patel, 2018). As such,
a more balanced routine that focuses on moderate intensity cardio workouts and weight training
may be more effective in boosting metabolism and promoting sustained weight loss and
management (Patel, 2018). Merkin et al. (2016) notes that resistance exercise is helpful in
increasing base metabolic rate through gaining muscle mass. Yet, there are still potential gaps in
research regarding what specific types of exercise programs may benefit PCOS patients the most.
Currently, the most important consideration is engaging in regular physical activity for
promotion of general wellbeing and prevention of DMII, obesity, and cardiovascular disease.
Weight Loss
Maintaining a healthy weight is a high priority for PCOS patients. When at a healthy
weight, there is less overall strain on the body and a higher potential for effective metabolic and
hormone regulation. It is less strenuous on pancreas pertaining to insulin production, which
promotes proper glucose usage and storage. Additionally, less adipose tissue also lessens the
propensity for high testosterone due to the hormonal feedback loops involved. Merkin et al.
(2016) discusses that “with a 5%–10% reduction in weight, hyperandrogenemia, ovarian volume,
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and menstrual cycle irregularity are improved and SHBG [sex hormone-binding globulin] is
increased” in addition to insulin sensitivity for most women (p. 19). Obesity is a prominent
exacerbating factor of PCOS that can be largely controlled through lifestyle changes. Yet,
maintaining a healthy weight does not necessarily eliminate all PCOS metabolic irregularities or
symptomatology. As such, weight loss is only one of many considerations in managing PCOS.
Stress Reduction
Lowering stress is a powerful way to help reduce illness and symptomatology for
numerous diseases (Halter, 2018). This is true for PCOS-IR patients as well, particularly due the
relationship between cortisol and insulin. Reducing stress lowers cortisol production and
inflammation within the body, which subsequently reduces the body’s demand for insulin. This
promotes proper regulation of the body’s metabolism and hormone levels. On the contrary, when
in fight or flight mode, the body cannot regulate the reproductive system properly. Sympathetic
nervous system (SNS) activation inhibits parasympathetic nervous system activity, therefore
disrupting carbohydrate digestion, insulin regulation, and reproductive hormone release. As
noted previously, elevated insulin promotes testosterone production, interfering with the
menstrual cycle and worsening PCOS symptoms. Some stress reduction techniques that may be
beneficial are journaling, cognitive reframing, meditation, relaxation exercises, or other calming
and enjoyable activities. In essence, elevated stress impacts mental well-being and plays a
significant role in pathological processes but can be managed through stress reduction methods
(Halter, 2018).
Counseling
Women with PCOS may benefit from receiving professional counseling, either in a group
setting or one-on-one sessions. Counseling may help patients manage stress, reduce anxiety and
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depression, address body image issues, and cope with infertility or other disease complications
(Halter, 2018). With proper counseling, individuals may be better equipped to manage their
condition and make healthier choices that affect both mental and physical health. Counseling
within the general population has shown to be effective in reducing distressing emotions and
promoting coping mechanisms (Halter, 2018). This can be expounded upon to PCOS populations
as well, as indicated by a clinical trial for PCOS patients that implemented the use of cognitive
behavioral therapy (CBT) for weight loss and improved quality of life (Cooney et al., 2018).
Another study conducted by Abdollahi et al. (2019) in Iran also indicated that CBT reduced the
prevalence of psychosocial fatigue and increased quality of life. CBT may be one of multiple
counseling methods appropriate for PCOS patients, demonstrating the need for assessing a
patient’s mental health status and the potential benefits of counseling. Consequently, nurses
should assess patients’ mental health and refer patients who exhibit symptoms of depression or
anxiety to therapeutic resources.
Dietary Supplements
Dietary supplements such as inositol and vitamin D are newer areas of research regarding
PCOS treatment. Other potential supplements not discussed within this review include, but are
not limited to, chromium and folate. The hope is that using these natural supplements addresses
the source of hormone imbalances and therefore reduces symptoms and PCOS complications.
Inositols
Inositols are known insulin-sensitizing agents produced by the body, including the
ovaries, in order to maintain physiologic activities (Roseff & Montenegro, 2020). Merkin et al.
(2016) along with Wojciechowska et al. (2019) found that the stereoisomer myo-inositol (MI) is
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beneficial in reduction of androgen excess and promotion of ovulation in PCOS patients.
Physiologically,
MI is converted to an inositolphosphoglycan (IPG) insulin second messenger (MI-IPG)
involved in cellular glucose uptake, whereas DCI is converted to an IPG insulin second
messenger (DCI-IPG) involved in glycogen synthesis. At the ovarian level, however, it
has been shown that an MI-based second messenger is involved in both glucose uptake
and FSH signaling, whereas a DCI-based second messenger is devoted to insulinmediated androgen production (Roseff & Montenegro, 2020, p. 2).
The benefits of MI to d-chiro-inositol (DCI) are most effective when consumed in a 40:1 ratio,
which mimics the body’s natural production; 2-4 grams of MI per day is the typical
recommended dosage for hormone regulation and promotion of ovulation (Merkin et al., 2016;
Wojciechowska et al., 2019). However, Roseff and Montenegro (2020) discuss that DCI when
given alone or in improper doses is an aromatase inhibitor and may elevate androgen levels. A
study by Facchinetti et al. (2019) comparing the short-term effects of MI to metformin as insulinsensitizing agents found both yielded similar metabolic improvements, however, metformin had
significantly more side effects and potential complications.
Roseff and Montenegro (2020) reiterate that supplements should be chosen based upon
scientific data, patient-specific needs, and therapeutic rationales. As such, women considering
inositol supplements should discuss this with their physicians and do adequate research regarding
supplement brands, safety, and efficacy. Further research should be conducted to evaluate
current supplement options, long-term effectiveness for ovulation management and insulin
sensitivity, and the potential for a Food and Drug Administration (FDA) approved medication
containing inositols.
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Vitamin D
Vitamin D has been shown to have a positive effect on insulin production and usage,
which is beneficial for glucose metabolism (Merkin et al., 2016). Many women may not meet the
daily recommended dose of vitamin D through diet and sun exposure alone, which further
demonstrates the benefits of vitamin D supplementation for PCOS women. This is further
supported a systematic review and meta-analysis of trials involving PCOS and vitamin D
supplementation conducted by Łagowska, Bajerska, and Jamka’s (2018), which concluded that
vitamin D supplementation alone or when paired with other medications and supplements can
improve insulin sensitivity.
A randomized, placebo-controlled clinical trial by Kadoura et al. (2019) studied the
effects of combining calcium and vitamin D supplements with metformin for PCOS patients.
They found that both can support aims to regulate menstruation and promote insulin sensitivity.
However, no statistically significant differences in gonadotrophins or IGF-1 systems were
present. They noted that the underlying mechanisms of vitamin D usage, including when in
combination with metformin, must be researched further (Kadoura et al., 2019).
PCOS patients should strongly consider having their vitamin D levels checked and
implementing supplementation under the consultation of a physician. Having the proper levels of
vitamin D is a relatively simple way to encourage proper metabolism and manage IR and its
associated consequences.
Pharmacologic Interventions
Metformin
According to Balen et al. (2016), metformin monotherapy, while typically used for DMII,
can be effectively utilized in women with PCOS-IR due to its ability to decrease serum insulin
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levels and improve PCOS symptoms. The mechanism of action of metformin includes
decreasing hepatic glucose production, stimulating hepatic and skeletal insulin-mediated glucose
uptake, and reducing serum lipids through inhibited substrate availability involved in
gluconeogenesis. According to Balen et al. (2016), metformin should be implemented prior to
other insulin-sensitizing agents, such as thiazolidionediones and myo-inositol, due to a higher
benefit-to-risk ratio and a current lack of evidence. Though weight loss is not classified as a side
effect, metformin may enhance a woman’s ability to lose weight related to its regulation of
insulin utilization, thus reducing IR while also decreasing symptoms (Balen et al., 2016).
Kriedt et al. (2019) discusses that metformin may be used individually or in combination
with CC or letrozole as an adjuvant treatment for ovulation induction. The typical dosage for this
purpose is around 1500 mg per day. Especially when in combination with another medication for
ovulation induction, metformin has shown to be clinically beneficial for conception and
pregnancy. This is particularly encouraging for PCOS women with prediabetes or DMII who are
likely already using metformin to manage this comorbidity (Kriedt et al., 2019). For those who
utilize metformin alone for ovulation and conception purposes, they have poorer outcomes than
when used in conjunction with clomiphene citrate (CC) or another ovulation-stimulating
medication (Balen et al., 2016). It is also critical to note that metformin does not affect rates of
miscarriage for women, especially for those who experience progesterone deficiencies (Balen et
al., 2016).
As explained by Balen et al. (2016), metformin is primarily processed through the liver,
which may be impaired if women have NAFLD with altered liver enzymes. Women should have
their liver enzymes tested prior to prescribing metformin and periodically while taking the
medication to ensure the healthy liver function and prevent complications. Additionally, the
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commonality of gastrointestinal upset as a side effect of metformin decreases the likelihood of
medication compliance. Gastrointestinal upset may also alter dietary intake and nutritional status,
which may further negatively affect patient health and well-being. As such, these and other
potentially serious side effects of metformin must be evaluated, especially considering many
patients may be prescribed these medications long-term (Balen et al., 2016).
There are multiple potential questions that arise from this research. Since metformin is
typically prescribed long-term, can metformin impair the function of pancreatic alpha cells over
time? If so, does the short-term benefit of metformin in promoting insulin-sensitivity lead to
long-term complications and the promotion of DMII development? Subsequently, research as to
the duration of metformin’s effectiveness should be evaluated. When prescribing medications for
treatment, both short- and long-term considerations must be made. Currently, metformin is one
of the first-line medications for PCOS-IR, yet there are no clear guidelines as to when or how
metformin therapy should be initiated beyond the fact that lifestyle modification should be
attempted first. As such, more clear delineation of metformin therapy for PCOS-IR should be
researched to have the safest, most beneficial outcomes for women.
Hormonal Birth Control
The various hormonal birth control medications utilized for PCOS have multiple
applications. Common examples of birth control options include COCs and intrauterine devices
(IUDs). There are numerous types within each of these categories that have various chemical
compositions and mechanisms of action. Consequently, birth control as a treatment option will
be discussed as a category and not include specific COC or IUD options.
Birth control is primarily meant for hormonal regulation and protection against
endometrial hyperplasia in PCOS (Sanoski & Vallerand, 2019). This is a protective measure to
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help preserve fertility in the future and reduce the risk of endometrial cancer. Birth control may
also reduce symptoms such as acne and hirsutism (Sanoski & Vallerand, 2019). Yet, birth
control does not address the underlying causes of PCOS’ hormonal abnormalities that affect
reproductive health and there is question as to whether these options have substantive impacts on
patients’ quality of life (Altinok et al., 2018).
The ideal contraceptive for women with PCOS should be [sic]: limit antral follicle
development and reduce androgen levels; counter the action of androgens on the
pilosebaceous unit at peripheral level; restore the balance between estrogens and
progesterone in the endometrium, ensuring good control of the menstrual cycle. For these
women, an OC [oral contraceptive] containing 30 mg ethinylestradiol (EE) is the most
indicated, because it ensures good control of the cycle and reduces ovarian androgen
production in all phases of the cycle. This formulation also effectively stimulates liver
production of SHBG, more than OCs with lower doses of EE [14,15]. SHBG binds and
transports testosterone (T) into circulation. Thus, higher production of SHBG leads to a
greater percentage of bound (inactive) T and less fT [free testosterone], giving the OC a
greater antiandrogen effect (Morgante et al., 2018).
As mentioned previously, birth control may have major side effects such as
hypercholesterolemia, blood clots, mood liability or depression, particularly for those with other
risks factors such as cardiovascular disease or being above 35 years old (Sanoski & Vallerand,
2019). These are serious risks to consider for PCOS patients, especially because of PCOS’ many
potential sequelae. Unfortunately, many patients suffer side effects of medication in conjunction
with PCOS symptoms because they lack knowledge or feel as if there are no other disease
management options. For patients with NAFLD or other liver conditions that elevate liver
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enzymes, patients are unable to take birth control medications because they are metabolized
through the liver and may worsen liver damage (Sanoski & Vallerand, 2019). These patients
require other types of PCOS treatment that is often not considered. Additionally, healthcare
providers may neglect to check liver enzymes and other important lab values prior to prescribing
birth control, leaving patients vulnerable to various medication complications. For patients who
do not wish to take hormonal birth control for personal reasons, such religious beliefs, or due to
medical contraindications, other PCOS management options should be offered by their
physicians.
Progesterone Only Medication
POPs, such as medroxyprogesterone, are often regarded as a second choice for prevention
of endometrial hyperplasia if patients cannot take hormonal birth control (Sanoski & Vallerand,
2019). POPs are often prescribed for 5-10 days. The cessation of the medication causes a drop in
progesterone levels, stimulating menstruation to occur. Patients are instructed to take the POPs
once every 1-3 months depending on the specific medication and whether the patient has
menstruated on their own within the designated timeframe. While these medications are similar
to birth control concerning their ability to stimulate menstruation upon cessation, they are not
effective as contraception and do not have the same protective nature. (Sanoski & Vallerand,
2019;).
POPs may interfere with glucose regulation and cause hyperglycemia, especially for
those with prediabetes or DMII (Sanoski & Vallerand, 2019). This is a serious effect considering
the likelihood of IR in PCOS patients. Additionally, could POPs further interfere with PCOS
patients’ hormone regulation, leading to reduced ovulation and higher long-term sequelae?
Though general side effects are minimal for most women, further research should be considered
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regarding the long-term consequences of abnormal patterns of hormone ingestion on the
reproductive system.
Antiandrogens
Morgante et al. (2018) states that antiandrogen medications, such as spironolactone, are
utilized to decrease hirsutism and acne among PCOS patients. Treatment usually must last longer
than 6 months to receive the full effect in reducing hirsutism due to their impacts on terminal
hair growth. These medications are typically second-choice if COCs are not effective. Current
research indicates that they do not have the same impacts on estrogen and progesterone
regulation as COCs. As such, they are not considered effective in addressing the other
consequence of PCOS-related hormone imbalances (Morgante et al., 2018). However,
considering the relationship between hyperandrogenism and PCOS-IR, further research is
indicated to evaluate whether types of antiandrogen treatments could reduce the negative effects
of hyperandrogenism on ovulation. Depending on the side effects of the specific antiandrogen
medications, treatment may be contraindicated and should only be initiated after a
comprehensive evaluation by a physician.
Assisted Reproductive Medication and Technology
While there are many women with PCOS who conceive naturally, Kriedt et al. (2019)
and Balen et al. (2016) discuss that it is the most common cause of anovulatory infertility. As
such, PCOS patients desiring to conceive may need medical intervention to do so. The first steps
to address infertility are understanding the underlying causes specific to each woman. These may
include imbalances of reproductive hormones, being overweight or obese, and ovarian qualities.
For women who are overweight or obese, weight reduction through dietary changes and exercise
may be enough to improve the regularity of the menstrual cycle and frequency of ovulation
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enough to promote conception. In other instances, weight reduction does not significantly
improve hormonal regulation or ovulation frequency. Besides proper disease management noted
earlier, the primary treatments to pregnancy are medications that promote ovulation. Other
options include gonadotrophins, laparoscopic ovarian drilling (LOD), and assisted reproductive
technology (ART). Invitro fertilization (IVF) is often not considered for PCOS due to the risk of
ovarian hyperstimulation syndrome. Pharmacological interventions detailed within the realm of
this paper for PCOS include CC, aromatase inhibitors, metformin, and gonadotrophins (Kriedt et
al., 2019; Balen et al., 2016).
Clomiphene Citrate. Sanoski and Vallerand (2019) along with Kriedt et al. (2019)
explain that CC blocks estrogen receptors to increase GnRH pulsatility and gonadotrophin
secretion to promote ovarian follicular development and ovulation. Research demonstrates that
CC is often successful in inducing ovulation in many women. Onset of ovulation should occur
within 5-14 days after completing a course of the medication. For the medication to work
properly, anterior pituitary, thyroid, and adrenal function must be present. Additionally, the
medication is metabolized by the liver and should not be given to women who have liver disease
or dysfunction. Other potential contraindications or cautions when using CC include pituitary
tumors, undiagnosed uterine bleeding, endometriosis, and fibroids. There is always a risk of
multiple pregnancy when using CC, so this must be monitored. Some women may experience
side effects such as headaches, vision abnormalities, hot flashes, abdominal discomfort and
irregularities, elevated liver enzymes, ovarian cyst formation or ovarian enlargement, weight
gain, or ovarian hyperstimulation syndrome (OHSS). These side effects are potentially serious
and should be evaluated on a patient-by-patient basis. OHSS states that the symptoms of OHSS
may include ascites, pleural or pericardial effusions, and gastrointestinal upset. If left untreated,
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OHSS may be fatal (Sanoski & Vallerand, 2019; Kriedt et al., 2019). Though there is the
potential for successful conception, PCOS patients must consider the significant risks of
complications, such as OHSS, prior to taking CC. Mental and physical well-being should be a
high priority.
Sanoski and Vallerand (2019) along with Kriedt et al. (2019) state that typical dosage for
ovulatory failure is 50 mg per day for 5 days beginning on the 5th day of the menstrual cycle. If
this does not induce ovulation, a second course of 100 mg per day for 5 days may be 30 days
later. If the ovaries are hyperresponsive, a lowered dose of 25 mg per day may be indicated.
More than 3 courses of medication should not be administered back to back; if patients do not
successfully conceive after more than 6-12 months of medication intervention with CC, a
different treatment regimen should be considered. Patients should be instructed to take the
medication at the same time every day. Beginning 48 hours prior to anticipated ovulation, the
patient should engage in sexual intercourse every other day throughout the ovulatory period to
increase the chance of conception. Prior to and during medication usage, the patient should be
evaluated for ovarian characteristics, liver function, hormone levels, and other relevant health
characteristics. Ultrasound monitoring should be done to evaluate endometrial development and
optimal intercourse timing (Sanoski & Vallerand, 2019; Kriedt et al., 2019).
As indicated, CC may be a beneficial option for women who desire to conceive. Yet, it
may not be effective or safe for all women as each patient has unique factors to consider. Further
research could be initiated regarding the potential for creating medication similar to CC for
general regulation of ovulation without the high risk of increased cysts and ovarian
hyperstimulation. Additionally, potential long-term health risks should be evaluated for those
who receive numerous doses of CC.
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Aromatase Inhibitors. Aromatase Inhibitors, specifically letrozole, are given to reduce
levels of estrogen and are typically used to treat certain types of breast cancers or for stimulation
of ovulation for with infertility. Kriedt et al. (2019) discusses that aromatase inhibitors inhibit the
conversion of androgens into estrogens to promote ovulation as estrogen levels drop and FSH
and LH are stimulated. A meta-analysis conducted by Franik et al. (2018) concluded that there is
substantive evidence for the use of letrozole for PCOS patients due to its effectiveness in
stimulating ovulation and facilitating pregnancy. Additionally, Franik et al. (2018) concluded
that letrozole may be more effective than CC while having similar risks for OHSS, miscarriage,
or multiple pregnancy. A systematic review by Gadalla et al. (2020) reported the same findings;
letrozole improves ovulation, pregnancy, and live birth rates in a statistically significant manner
compared to CC with or without metformin. As such, Gadalla et al. (2020) states that letrozole
should be considered an alternative first line treatment for ovulation induction to CC. Kriedt et
al. (2019) also states that letrozole does not cause anti-estrogenic effects within the uterus or
cervix, which is beneficial for pregnancy related to follicle development and preservation of
feedback mechanisms between the ovaries and pituitary gland.
Side effects of aromatase inhibitors identified by Balen et al. (2016) include headaches,
back pain, gastrointestinal problems, hot flashes, and asthenia. There is some concern regarding
fetal safety and teratogenic effects as well; however, research supporting this is limited (Balen et
al., 2016). Overall, further research regarding side effects, effects on androgen levels, and longterm consequences of letrozole with repeated doses should be conducted. Patients considering
letrozole versus other methods of fertility treatments must heavily weigh the pros and cons of
each with their physician due to the individualized, multifactorial nature of infertility and fertility
treatment options.
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Gonadotrophins. Kriedt, et al. (2019) and NICHD Staff (2017b) explain that
gonadotrophins are considered second-line therapy and are reserved for circumstances where
other medications were proven ineffective or caused significant side effects that prohibited
further use. Additionally, they may be used as part of ART to facilitate follicle growth.
Gonadotrophins, typically FSH, are given by subcutaneous injection. These medications require
daily monitoring and patient-specific low dose regimens to reduce potential complications such
as multiple pregnancy and OHSS. Monitoring should include transvaginal ultrasound to evaluate
ovum development and bloodwork to monitor hormone levels, specifically estrogen production.
Multiples occur at a higher rate with gonadotrophins than with CC or letrozole. Although this is
typically not a dangerous result, it is something that must be taken into consideration prior to
initiating the medication (Kreidt et al., 2019; NICHD Staff, 2017b).
Balen et al. (2016) elaborates that low dose step-up regimens or step-down regimens
should be implemented to reduce the risks of ovarian overstimulation. However, the low dose
step-up regimen may necessitate a treatment cycle of 28-35 days. The benefits of this form of
gonadotrophin therapy must be weighed against the length of treatment and patient compliance.
On the other hand, a shorter, higher dose regimen typically has higher risks of multiples and
overstimulation that may negatively impact both maternal and fetal health. In either case,
determining the best dosage is a difficult due to its patient specific nature and the variability of
hormones. It can be concluded that the safest, most effective regimen of gonadotrophins should
be used, which typically involves the lower dose step-up regimen (Balen et al., 2016).
Balen et al. (2016) further explains that three or more follicles are above 14 mm in size,
the patient is at significant risk of OHSS and other complications. Therefore, gonadotrophin
therapy will be discontinued, and sexual intercourse is not advised until levels resolve. The
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benefits of gonadotrophin therapy are dependent upon individual patient factors, but primarily
involve the successful induction of ovulation and conception of a singleton pregnancy for
patients who are resistant to CC therapy (Balen et al., 2016).
Laparoscopic Ovarian Drilling. Mitra et al. (2015) explain that LOD is a surgical
procedure conducted with general anesthesia that involves electrocauterization or laser removal
of parts of the ovaries that overproduce androgens in aims of restoring regular ovulatory
menstrual cycles. Typically, both ovaries are done at once, with 4 locations drilled per ovary for
4 seconds at 40 joules. Patients usually return home the same day of the procedure and may
return to normal activity levels within a few days, or up to 2 weeks depending on individual
recovery time (Mitra et al., 2015).
Kreidt et al. (2019) along with Balen et al. (2016) discuss that LOD has similar efficacy
to gonadotrophins without the risks of multiples of OHSS. PCOS patients are more likely to
benefit from LOD if they have high levels of LH; however, hyperandrogenism, obesity, and
other factors may reduce the likelihood of effectiveness of LOD for ovulation induction. Risks
associated with LOD may include postoperative adhesions, damaging the ovarian reserve, and
other risks associated with surgical procedures like infection, bleeding, and accidental injury.
LOD serves as a way to temporarily increase the likelihood of ovulation and conception, but
does not solve the underlying condition and will not address any other clinical manifestations a
patient may experience. Patients should be carefully selected for LOD due to its potentially
damaging effects to long-term ovarian function, decreased ovarian reserve, and future fertility
(Kriedt et al., 2019; Balen et al., 2016).
Mitra et al. (2015) elaborate that the exact mechanism of action is not yet determined.
However, the currently supported theory involves the consequential rise in FSH after the
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destruction of some ovarian follicles and decreased androgen levels. This may be combined with
increased insulin-like growth factor-1 and gonadotrophin delivery related to the inflammation
and bodily response to surgery. Success of LOD varies per person depending on other pertinent
factors, such as the patient’s androgen levels, weight, and severity of IR. Rates of miscarriage are
low, as are the risks of multiples. The marked improvement in reproductive hormone release and
regularity demonstrates the effectiveness of LOD. However, as mentioned previously, these
results will likely only last for a year or so due to the chronic endocrine dysfunction present with
PCOS. LOD is seen as more cost-effective than gonadotrophin therapy and has less need for
monitoring. After a LOD procedure, anovulation for 6-8 weeks or failure to conceive for 12
months with regular ovulation is considered a failure. However, other ovulation induction agents
may be considered due to the increased responsiveness to the ovaries after LOD. Repeating
LOD, even after multiple years between procedures, is typically not conducted due to the
increased risk of adhesions and premature ovarian failure (Mitra et al., 2015).
Nursing Considerations and Patient Education
PCOS patients must consider a myriad of information upon diagnosis and throughout
their lives as they manage their condition. Many patients, especially those who have low health
literacy levels, may not understand the nuances of PCOS management without sufficient
teaching. Nurses and other healthcare professionals must consider the extensive systemic
ramifications of PCOS, including cardiovascular, endocrine, metabolic, and psychological, and
the immense need for high-quality patient education. While this is most critical in women’s
health and endocrinology, medical professionals in all specialties need a comprehensive
understanding of PCOS considering its numerous complications and prevalence among females.
Holistic, comprehensive healthcare across a multitude of specialties provides the best care for
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PCOS patients and may significantly improve outcomes. As such, registered nurses and
advanced practice nurses have both the responsibility to and unique capabilities for educating
PCOS patients and advocating on their behalf to achieve the level of care required to follow
evidence-based practice.
The hands-on care and rapport developed between nurses or advanced practice nurses and
patients have the potential to greatly affect patient outcomes. Foundationally, nurses can improve
patient health and wellbeing by simply listening to symptoms and patient concerns. A thorough
assessment may reveal symptoms, such as abnormal menstruation, hirsutism, and weight gain,
that all are all connected to PCOS. This is the first step in diagnosing PCOS and its
complications, followed by reporting the findings and taking proper action. Any symptom or
concern warrants investigation and discussion to thoroughly promote health. Nurses are called to
be patient advocates, which entails caring about their situation and initiating necessary actions.
Additionally, nurses are key contributors to patient education, providing key information on
disease prevention and treatment options during their conversations with patients. This requires
nurses to be educated on treatment options and effectively communicate when patients have
questions or lack sufficient knowledge to make informed decisions regarding their healthcare.
This often begins with education about healthy diet and exercise and encouraging patients to
engage in other regular health maintenance activities. Preventative education may help patients
pursue comprehensive management of their well-being, both physical and mental. In essence,
nurses and nurse practitioners have the power to change outcomes by equipping and empowering
PCOS patients with practical knowledge.
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Conclusion
The extensive research compiled for this integrative review revealed promising research
developments along with multiple gaps in the literature for PCOS patients. Although treatments
are improving, there remains a need for gynecologic and obstetric research. PCOS patients often
lack resources for disease management, particularly because they do not receive sufficient
education or have adequate long-term medical counseling (Cooney & Dokras, 2018). This
inhibits disease management, worsens health outcomes, and drastically elevates healthcare costs
for this patient population throughout the lifespan (Cooney & Dokras, 2018). Hormonal birth
control and assistive reproductive medications or procedures may help patients to some extent,
but they do not address the source of the hormone and metabolic abnormalities associated with
PCOS, especially PCOS-IR.
The complicated, multifactorial nature of PCOS, while puzzling and difficult to treat, also
presents opportunities for research in numerous areas. Further research should continue to
evaluate the etiology of PCOS, particularly any genetic links. Additionally, maternal influences,
particularly androgen levels and PCOS diagnosis, should be researched. Currently, research
indicates a correlation between maternal hyperandrogenism or PCOS and the prevalence of
PCOS in female offspring, however, more evidence is necessary to determine the connection.
For example, should women’s testosterone levels be tested during pregnancy? Subsequently, if
hyperandrogenism is present, are there medications or other ways to regulate testosterone and
reduce the potential for PCOS in offspring? Similar questions can be asked of AMH levels. For
women who have excessive AMH, can this be inhibited in some way to allow for proper
ovulation? PCOS has been correlated with multiple conditions, including endometriosis and
autism spectrum disorder (ASD). Thus far, maternal hyperandrogenism in utero along with fetal
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genetic changes in the CYP17A1, CYP19A1, and CYP11B1 pathways have been linked to both
ASD and PCOS, especially when mothers have PCOS and its resulting endocrine abnormalities
(Fillipou & Homburg, 2017). These connections and others must be further investigated for
genetic and etiologic similarities to progress potential treatment and management options.
As indicated throughout the research, efforts to maintain a healthy weight and other
lifestyle factors that reduce IR are a foundational component of PCOS care. Yet, countless
women with PCOS are ill-equipped to implement these changes due to a lack of education and
empowerment. The current pharmacological treatment modalities primarily involve hormonal
birth control options, with metformin for IR if necessary. However, birth control does not resolve
the underlying problems associated with PCOS and may be ineffective or contraindicated in
some patients. This brings into question whether physicians are quick to prescribe medications
without educating patients on other PCOS management strategies.
Overall, research suggests that comprehensive care, including diet, exercise, and
supplements must be an integral part of PCOS management. However, further research is
necessary to evaluate specific dietary recommendations, exercise types, and potential
supplements, particularly inositols, for PCOS management. Additionally, evaluating the potential
benefits of providing PCOS patients with a nursing case manager for long-term disease
management should be considered. The prevalence of PCOS and its potential ramifications
indicate the need for both more extensive research and higher quality patient education to help
improve their quality of life.
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